Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Bruno Julianne, the Chief Operating Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), has recently sold a portion of the company’s stock. On March 21, Julianne sold 1,714 shares at a price of $41.23 each, totaling approximately $70,668. The stock, which has shown significant volatility with a beta of 1.76, currently trades at $42.62, representing a 4.73% gain year-to-date. InvestingPro analysis indicates the stock is fairly valued, with comprehensive metrics available in the Pro Research Report.
The transaction was part of a mandatory sale to cover tax obligations associated with the vesting of restricted stock units, as stipulated by the company’s RSU Settlement Policy. Following this sale, Julianne holds 10,544 shares directly. Additionally, 7,088 shares are held indirectly through The Julianne Bruno 2022 GRAT.
On March 20, Julianne also acquired 3,750 common shares through the exercise of restricted stock units, although this transaction did not involve any cash exchange. For deeper insights into CRISPR Therapeutics’ insider transactions and comprehensive financial analysis, visit InvestingPro, where you’ll find exclusive ProTips and detailed valuation metrics.
In other recent news, CRISPR Therapeutics has been the focus of several analyst reports, emphasizing its earnings and pipeline developments. Citi analysts have maintained a Buy rating for CRISPR Therapeutics, although they reduced the price target from $89 to $82, citing the progress of Casgevy with over 50 treatment centers activated globally. Evercore ISI upgraded CRISPR Therapeutics from In Line to Outperform, raising the price target from $60 to $99, driven by optimism about future catalysts and the company’s strong cash position of $1.9 billion. Stifel analysts also adjusted their outlook, lowering the price target to $49 while maintaining a Hold rating, expressing caution about the market uptake of Casgevy. Meanwhile, TD Cowen upgraded CRISPR Therapeutics from Sell to Hold, keeping the price target at $35, acknowledging reduced downside risk for the company’s shares.
Evercore ISI analysts are particularly optimistic about the company’s in vivo programs, CTX320 and CTX310, which have been factored into their revised price target. Stifel, on the other hand, expressed a cautious stance due to stringent safety requirements for in vivo gene editing treatments. Despite differing opinions on the stock’s immediate potential, analysts generally agree on the importance of CRISPR Therapeutics’ pipeline developments, with significant updates expected in 2025. Investors are closely watching CRISPR Therapeutics as it navigates these developments and the anticipated progress of its gene-editing therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.